Lack_NN
of_IN
T-cell-mediated_JJ
recognition_NN
of_IN
the_DT
fusion_NN
region_NN
of_IN
the_DT
pml\/RAR-alpha_NN
hybrid_NN
protein_NN
by_IN
lymphocytes_NNS
of_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
patients_NNS
._.

In_IN
previous_JJ
studies_NNS
,_,
it_PRP
was_VBD
shown_VBN
that_IN
the_DT
fusion_NN
region_NN
of_IN
the_DT
pml\/RAR-alpha_NN
protein_NN
,_,
expressed_VBN
by_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
cells_NNS
,_,
can_MD
be_VB
specifically_RB
recognized_VBN
in_FW
vitro_FW
by_IN
donor_NN
-LRB-_-LRB-
D._NNP
E._NNP
-RRB-_-RRB-
CD4_NN
T_NN
cells_NNS
in_IN
a_DT
HLA_NN
class_NN
II_CD
DR11-restricted_JJ
fashion_NN
._.

We_PRP
present_VBP
here_RB
the_DT
results_NNS
on_IN
the_DT
recognition_NN
of_IN
several_JJ
pml\/RAR-alpha_NN
peptides_NNS
by_IN
APL_NN
patients_NNS
expressing_VBG
HLA_NN
DR11_NN
._.

The_DT
in_FW
vitro_FW
immunization_NN
of_IN
peripheral_JJ
blood_NN
lymphocytes_NNS
from_IN
four_CD
patients_NNS
in_IN
remission_NN
-LRB-_-LRB-
S.R._NNP
,_,
F.R._NNP
,_,
M.M._NNP
,_,
P._NNP
G._NNP
-RRB-_-RRB-
with_IN
BCR1\/25_NN
,_,
a_DT
25-mer_NN
pml\/RAR-alpha_NN
,_,
did_VBD
not_RB
elicit_VB
either_CC
a_DT
polyclonal_JJ
or_CC
a_DT
clonal_JJ
immune_JJ
response_NN
specific_JJ
to_TO
the_DT
peptide_NN
._.

We_PRP
then_RB
generated_VBD
new_JJ
donor_NN
anti-pml\/RAR-alpha_JJ
CD4_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
T-cell_NN
clones_NNS
._.

These_DT
clones_NNS
were_VBD
tested_VBN
for_IN
their_PRP$
recognition_NN
of_IN
BCR1\/25_NN
._.

One_CD
clone_NN
-LRB-_-LRB-
C3\/5_NN
,_,
CD3_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
,_,
CD4_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
,_,
CD8_NN
-LRB-_-LRB-
-_NN
-RRB-_-RRB-
-RRB-_-RRB-
was_VBD
selected_VBN
for_IN
further_JJ
analysis_NN
._.

Clone_NN
C3\/5_NN
showed_VBD
specific_JJ
proliferation_NN
,_,
cytotoxicity_NN
,_,
and_CC
cytokine_NN
-LRB-_-LRB-
tumor_NN
necrosis_NN
factor_NN
alpha_NN
,_,
granulocyte-macrophage_JJ
colony-stimulating_JJ
factor_NN
-RRB-_-RRB-
production_NN
when_WRB
challenged_VBN
with_IN
autologous_JJ
lymphoblastic_JJ
cell_NN
lines_NNS
pulsed_VBN
with_IN
peptide_NN
BCR1\/25_NN
._.

C3\/5_NN
cells_NNS
developed_VBD
specific_JJ
proliferation_NN
and_CC
cytotoxicity_NN
when_WRB
challenged_VBN
with_IN
peptide-pulsed_JJ
lymphoblastic_JJ
cell_NN
lines_NNS
and_CC
peripheral_JJ
blood_NN
lymphocytes_NNS
from_IN
the_DT
four_CD
DR11_JJ
-LRB-_-LRB-
+_JJ
-RRB-_-RRB-
APL_NN
patients_NNS
._.

APL_NN
blasts_NNS
,_,
available_JJ
only_RB
from_IN
patients_NNS
F.R._NNP
and_CC
P.G._NNP
,_,
were_VBD
not_RB
lysed_VBN
by_IN
C3\/5_NN
and_CC
were_VBD
unable_JJ
to_TO
present_JJ
peptide_NN
BCR1\/25_NN
._.

Incubation_NN
of_IN
APL_NN
cells_NNS
with_IN
IFN-gamma_NN
failed_VBD
to_TO
induce_VB
HLA_NN
class_NN
II_CD
molecules_NNS
and_CC
recognition_NN
by_IN
the_DT
C3\/5_NN
clone_NN
._.

Since_IN
APL_NN
cells_NNS
do_VBP
not_RB
express_VB
HLA_NN
class_NN
II_CD
molecules_NNS
,_,
we_PRP
tested_VBD
in_IN
two_CD
donors_NNS
-LRB-_-LRB-
D.E._NNP
and_CC
C.H.R._NNP
-RRB-_-RRB-
and_CC
in_IN
patients_NNS
S.R._NNP
and_CC
P.G._NNP
whether_IN
the_DT
use_NN
of_IN
9-mer_NN
peptides_NNS
-LRB-_-LRB-
BCR1\/9_NN
-RRB-_-RRB-
would_MD
generate_VB
a_DT
CD8\/HLA_NN
class_NN
I-restricted_JJ
response_NN
._.

No_DT
peptide-specific_JJ
T-cell_NN
line_NN
or_CC
clone_NN
could_MD
be_VB
generated_VBN
from_IN
both_CC
donors_NNS
and_CC
patients_NNS
._.

These_DT
findings_NNS
are_VBP
discussed_VBN
in_IN
relation_NN
to_TO
possible_JJ
therapeutic_JJ
approaches_NNS
to_TO
the_DT
immunotherapy_NN
of_IN
APL_NN
._.

